Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Call For Papers

Clinical, Cosmetic and Investigational Dermatology

ISSN: 1178-7015


The following Article Collections/ Thematic Series are currently open for submissions:

Hyaluronic acid fillers: superficial injections vs tridimensional injections, what changes?

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection: “Hyaluronic acid fillers: superficial injections Vs tridimensional injections, what changes?” organized by Guest Advisors Professor Raffaele Rauso and Professor Nicola Zerbinati in Clinical, Cosmetic and Investigational Dermatology.

Since the beginning of the 21st century, hyaluronic acid (HA) fillers have become a mainstay in aesthetic medicine; these fillers have been quickly appreciated by both physicians and patients due to HA safety and their temporary effect. HA fillers were born as “dermal filler” in order to be injected in the dermal layer to treat fine lines, but over time physicians understood how to inject them tridimensionally, not only into the skin layer but also in superficial and deep facial fat compartments or over the periosteum in order not only to treat lines but to achieve deep facial feature changes.

Although HA is an absorbable substance when injected into the dermal layer due to the action of endogenous hyaluronidase, when injected deeply it has a different pattern of resorption, sometimes lasting also several years. Not all physicians are aware of this and continuing to inject HA fillers every 6 to 8 months causes, over the years, accumulation of the filler into the face, achieving unpleasant results of “puffy face”. Also the use of hyaluronidase, in order to dissolve HA fillers previously injected, has increased during recent years as shown in the recent medical literature.

Nowadays, most aesthetic patients have the stigmata of previous HA injections and a good physician should be aware of it in order to avoid areas where HA is still present, moreover it is mandatory to have a good knowledge of hyaluronidase uses, especially when an unpleasant result is long-lasting and HA needs to be dissolved in order to repeat the treatment in the right way.

The aim of this collection is to provide scientifically based papers that can give readers a guide on how to approach patients previously injected with HA fillers over the years, potential complications in injecting deep areas already injected, and when and how to use hyaluronidase before to repeat a filler treatment.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 1 March 2024

Please submit your manuscript on our website, quoting the promo code MWJLR to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Teledermatology, Inflammatory Skin Disorders and COVID-19: What the Experience Has Taught Us

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection on “Teledermatology, Inflammatory Skin Disorders and COVID-19: What the Experience Has Taught Us” in Clinical, Cosmetic and Investigational Dermatology.

The COVID-19 pandemic has drastically transformed healthcare delivery, forcing medical professionals to seek innovative ways to provide patient care while minimizing face-to-face interactions. Teledermatology, the remote diagnosis and treatment of skin conditions using telecommunication technologies, has emerged as a valuable tool in dermatology practice during this challenging time. This Article Collection explores the application of teledermatology in the context of inflammatory skin disorders and the lessons learned from the COVID-19 experience.

Inflammatory skin disorders encompass a wide range of conditions. These diseases often require long-term management and frequent follow-ups, making teledermatology a suitable alternative to traditional in-person visits. With the aid of secure digital platforms, dermatologists can remotely assess skin lesions, evaluate disease severity, and provide treatment recommendations. Patients can upload images of their skin lesions or participate in real-time video consultations, allowing dermatologists to make accurate diagnoses and initiate appropriate therapies. The COVID-19 pandemic has highlighted several key benefits of teledermatology for inflammatory skin disorders. Firstly, it reduces the risk of virus transmission by minimizing physical contact between patients and healthcare providers. This is particularly crucial for patients with chronic skin conditions who are at a higher risk of severe illness from COVID-19. Secondly, teledermatology enhances accessibility to specialized care, especially for individuals residing in remote areas or facing transportation barriers. It enables patients to receive expert advice without the need for long-distance travel, thereby improving healthcare equity.

However, the use of teledermatology in inflammatory skin disorders also comes with certain limitations. To address these limitations, dermatologists have adapted their practices and developed strategies for optimizing teledermatology services. Globally, the experience gained during the COVID-19 pandemic has emphasized the importance of incorporating teledermatology into routine dermatology practice beyond the crisis. Teledermatology has demonstrated its value in triaging patients, improving access to care, and facilitating timely interventions. It has the potential to reduce healthcare costs, decrease patient waiting times, and enhance overall patient satisfaction. Moving forward, efforts should be made to establish guidelines and policies to ensure the ethical practice of teledermatology while maintaining patient privacy and data security. In conclusion, the COVID-19 pandemic has accelerated the adoption of teledermatology in managing inflammatory skin disorders.

While there are certain limitations associated with remote consultations, the experience gained during the pandemic has taught us that teledermatology is a valuable tool for providing accessible and efficient care.

The deadline for submissions is 12 March 2024. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code ZOMSS to indicate that your submission is for consideration in this Article Collection.

Guest advisors

Luca Potestio, University of Naples

[email protected]

Matteo Megna, University of Naples 

[email protected]

Angelo Ruggiero, University of Naples 

[email protected]

Fabrizio Martora, University of Naples 

[email protected]

View all papers in this article collection

Hidradenitis Suppurativa: Insights from pathogenesis to treatment

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection on “Hidradenitis Suppurativa: Insights from pathogenesis to treatment” in Clinical, Cosmetic and Investigational Dermatology.

Hidradenitis suppurativa (HS) is an inflammatory disorder that is characterized by chronic deep-seated nodules, abscesses, fistulae, sinus tracts, and scars in the axilla, inguinal area, submammary folds, and perianal area. This disfiguring condition is accompanied by pain, embarrassment, and a significantly decreased quality of life. Although the mechanism of HS has not been entirely elucidated, lesion formation is believed to center around follicular hyperkeratosis within the pilosebaceous-apocrine unit. Recent research has provided new insight into the role of cytokines in the pathogenesis of HS, helping close some existing knowledge gaps in the development of this condition. Immune cells and keratinocyte-mediated products are widely accepted as key players in HS pathogenesis. Indeed, both pro-inflammatory (e.g., IL-1β, TNF-α, IL-23, and IL-17) and anti-inflammatory cytokines (e.g., IL-10) are found to be increased in HS lesional and perilesional skin.

The identification of predictive biomarkers of therapeutic response is one of the greatest challenges of modern medicine, particularly in a pathology as HS with a high percentage of therapeutic failures. Although several studies have shown that anti-TNF-α agents clinically reduce the disease activity in HS, the efficacy of these agents is inconstant in some cases. Identifying predictive markers of response is, thus, of strong interest. Several small molecules and biologics are under investigation, for moderate-to-severe HS therapy. With phase III trials ongoing, the anti-IL-17 agents bimekizumab (which blocks IL-17 A and F) and secukinumab (which blocks IL17A) are in the most advanced stage of clinical development showing promising results, based on the extensive evidence of the activation and upregulation of the IL-17 pathway in HS inflammation. Other molecules and biologics are under investigation such as jak inhibitors and IL-23 drugs. New studies are needed to identify biomarkers.

The Article Collection entitled: “Hidradenitis Suppurativa: Insights from pathogenesis to treatment” aims to bring together the most important recent findings on pathogenesis and treatments for this disease.

The deadline for submissions is 24 May 2024. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code HWNEN to indicate that your submission is for consideration in this Article Collection.

Guest advisors

Fabrizio Martora, University of Naples

[email protected]

Matteo Megna, University of Naples

[email protected]

Luca Potestio, University of Naples

[email protected]

View all papers in this article collection

Chronic inflammatory skin diseases: From pathogenesis to treatment

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection on “Chronic inflammatory skin diseases: From pathogenesis to treatment” in Clinical, Cosmetic and Investigational Dermatology.

Significant progress has been achieved in the last few decades in dermatology, especially regarding chronic inflammatory skin diseases. In recent years, great progress has also been made in understanding the pathogenesis of the most common inflammatory skin diseases such as psoriasis, atopic dermatitis, and hidradenitis suppurativa that has led to the development of selective and targeted innovative therapies. In particular, biological drugs (chimeric, humanized, and fully human monoclonal antibodies), biosimilars, and small molecules have completely revolutionized the treatment of chronic inflammatory skin diseases by opening new avenues for clinicians.

However, significant research efforts are still needed. New studies are needed to identify biomarkers for each disease, so that clinicians may be able to diagnose and treat chronic inflammatory diseases early and predict responses to treatments so that we can choose the best treatment for each type of patient.

All article types, including case reports, case series, original research articles, and review articles, are in line with the scope of this Article Collection.

This Collection welcomes submissions covering a range of related areas of chronic inflammatory skin diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata and others.

Keywords

  • Psoriasis
  • Hidradenitis Suppurativa
  • Atopic dermatitis
  • Alopecia areata
  • Skin inflammatory disease

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 15 July 2024. Please submit your manuscript on our website, quoting the promo code TSMRY to indicate that your submission is for consideration in this Article Collection.

Guest advisors

Fabrizio Martora, University of Naples Federico II, Italy

[email protected]

Matteo Megna, University of Naples Federico II, Italy

[email protected]

Teresa Battista, University of Naples Federico II, Italy

[email protected]

View all papers in this article collection


Call For Papers

Editor-in-Chief: Dr Jeffrey M Weinberg


To see where Clinical, Cosmetic and Investigational Dermatology is indexed online view the Journal Metrics.

What is the advantage to you of publishing in Clinical, Cosmetic and Investigational Dermatology?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although Clinical, Cosmetic and Investigational Dermatology receives a lot of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Clinical, Cosmetic and Investigational Dermatology has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
Clinical, Cosmetic and Investigational Dermatology is indexed on PubMed Central (title abbreviation: Clin Cosmet Investig Dermatol). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so.  Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Dr Jeffrey M. Weinberg 
Editor-in-Chief
Clinical, Cosmetic and Investigational Dermatology

Email: Editor-in-Chief

Related journals you may also be interested in: